Akums Drugs & Pharmaceuticals Ltd Financials
Company Logo

Akums Drugs & Pharmaceuticals Ltd Financial Statement

Akums Drugs & Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue343.45
Operating Expense273.59
Net Profit41.88
Net Profit Margin12.19
Earning Per Share2.93
EBIDTA69.99
Effective Tax Rate17.92

Akums Drugs & Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Total Revenue Annual1,286.83
Operating Expenses Annual1,088.92
Operating Profit Annual193.50
Interest Annual13.18
Depreciation26.62
Net Profit Annual125.43
Tax Annual24.89

Akums Drugs & Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Cash Flow at the Beginning25.49
Cash Flow from Operations94.01
Cash Flow from Investing-202.17
Cash Flow from Financing89.90
Cash Flow at the End7.23

Akums Drugs & Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
PBDIT Margin (%)25.91
PBIT Margin (%)23.58
PBT Margin (%)21.79
Net PROFIT Margin (%)9.75
Return On Networth / Equity (%)91.28
Return On Networth /Employed (%)20.84
Return On Assets (%)8.58
Total Debt / Equity (X)0.66
Asset Turnover Ratio (%)0.88

Akums Drugs & Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2023
Fixed Assets Annual253.27
Total Current Assets Annual521.08
Non Current Assets Annual1,373.13
Total Shareholders Funds Annual311.50
Total Assets Annual1,894.21

Akums Drugs & Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

4.21

Reported

4.21

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Jun 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Akums Drugs & Pharmaceuticals Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
No, Akums Drugs & Pharmaceuticals Ltd is not debt-free with a debt-to-equity ratio of 0.60.
In FY 2023 , Akums Drugs & Pharmaceuticals Ltd recorded a total revenue of approximately 1,286.83 Cr marking a significant milestone in the company's financial performance.
Akums Drugs & Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and 0.2% annually, respectively..
Akums Drugs & Pharmaceuticals Ltd's current PE ratio is undefined.
Akums Drugs & Pharmaceuticals Ltd's ROCE averaged 0.4% from the FY ending March 2021 to 2023, with a median of 4.7%. It peaked at 20.3% in March 2023, reflecting strong capital efficiency over the period..
Akums Drugs & Pharmaceuticals Ltd's latest EBIT is Rs. 163.50 Cr, surpassing the average EBIT of Rs. -120.74 Cr over the 5 years..